Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy

Plain-language summary

This study provides long-term follow-up of type 2 diabetes patients who were previously treated with an ex vivo gene therapy (a mesenchymal stem cell product) in an earlier clinical trial. It enrolls patients who received this treatment in that trial and agreed to take part in the follow-up. The study is a non-phase study; it is not currently recruiting but is ongoing (active, not recruiting).

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

Ukraine Association of Biobank

Intervention

Long term follow up

Start date

10/15/2020

Estimated completion

10/10/2030

Countries

Ukraine

Related genes

Locations

• Kharkiv, Ukraine

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Treated with gene therapy of diabetes 2 type in a drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study
* Able to comply with study requirements
* Provision of written informed consent for this study by subjects or as applicable subject legal/parent guardian

Exclusion Criteria:

* There are no exclusion criteria for this study